A US pharma company has successfully tested a Food and Drug Administration approved over the counter ointment as the first line of defense against the deadly coronavirus that has so far killed more than eight lakh people worldwide.
Scientists associated with the project said that the FDA-registered non-prescription over the counter (OTC) ointment has been proven to prevent, treat and kill viral infections, including coronavirus.
“As stated in the lab report, no infected virus was detected after 30 seconds of T3X treatment,” the pharma company said in a statement.
“We believe this will be a breakthrough that will reduce the chance of getting coronavirus infection through the nose, which is where most cases are contracted,” said Dr. Brian Huber, CEO and founder of Advanced Penetration Technology, based out of Indiana and Texas.
‘This is a big deal. It is the type of protection that many people have hoped for and could be a first line of defense against the COVID virus. It is a powerful and effective layer of prevention, “Huber said.
He says after the company released the results of an independent laboratory evaluation of a current medical formulation that reduces the coronavirus from entering the body through the nasal passages, thereby significantly reducing the chance of humans getting the virus.
A recent study by the Massachusetts Institute of Technology (MIT) concluded that humans contracted COVID-19 and other viruses primarily through the nose. However, virus can still enter a body through the mouth and eyes.
“T3X is an FDA registered, VAT formulation, which means no prescription is required. It is easy to use and can be managed even without the assistance of medical staff or technicians, “the company said.
A London-based laboratory, Virology Research Services Ltd, evaluated the anti-viral effect of the product, called APT ™ T3X, against Corona Virus (NL63) and Influenza A virus and concluded that it is a very effective formulation against coronavirus, it sei.
The study concludes that APT ™ T3X effectively neutralizes viral infectivity within seconds. The antiviral efficacy supports the current intranasal use of APT ™ T3X to reduce the viral load of exposure.
“Under the conditions tested, APT T3X shows a 99.9% virucidal activity against human coronavirus NL63,” the company said.
The test was conducted over two months, in May and June. All definitive anti-viral assays were performed in triplicate, it said.
The product was initially developed eight years ago for resistant bacterial infections, but its formulation also delivers powerful anti-fungal and anti-viral therapies. It has no documented side effects. However, patients diagnosed with Lyme disease should be aware of a potential “Herx” reaction shortly after use, the company said.
A total of 22,864,873 people have contracted coronavirus worldwide to date, according to the Johns Hopkins University COVID Resource Center.
.
